Crinetics Pharmaceuticals (CRNX) Stock Statistics & Valuation Metrics

Crinetics Pharmaceuticals has a market cap or net worth of $2.81B. The enterprise value is $3.38B.

Crinetics Pharmaceuticals has 93,048,540 shares outstanding. The number of shares has decreased by -2.65% in one year.

Crinetics Pharmaceuticals’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -24.52%.

The current PE Ratio of Crinetics Pharmaceuticals is -13.84. Crinetics Pharmaceuticals’s PEG ratio is 0.00.

In the last 12 months, Crinetics Pharmaceuticals had revenue of 1.04M and earned -298.41M in profits. Earnings per share was -3.69.

In the last 12 months, operating cash flow was -225.97M and capital expenditures -3.84M, giving a free cash flow of -229.81M billion.

Crinetics Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Crinetics Pharmaceuticals upcoming earnings date is May 8, 2025, TBA Not Confirmed.

Crinetics Pharmaceuticals as a current ratio of 23.04, with Debt / Equity ratio of 3.90%

In the past 12 months, Crinetics Pharmaceuticals has paid 0.00 in taxes.

Crinetics Pharmaceuticals EV to EBITDA ratio is -11.56, with an EV/FCF ratio of -17.05.

Crinetics Pharmaceuticals has $1.35B in cash and marketable securities with $0.00 in debt, giving a net cash position of -$1.30B billion.

Gross margin is -18.09%, with operating margin of -32613.47%, and net profit margin of -28720.69%.

The average price target for Crinetics Pharmaceuticals is $78.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy